AbbVie (ABBV) Stock Forecast & Price Target

AbbVie's financial outlook appears robust, with management increasing its 2025 revenue guidance to approximately $59.7 billion and non-GAAP EPS guidance to a range of $12.09-$12.29, reflecting positive performance drivers such as Skyrizi and Rinvoq. The neuroscience segment is also projected to generate global sales of about $10.7 billion, supported by strong contributions from products like Botox Therapeutic and Vraylar. Additionally, recent quarterly earnings surpassed expectations with total sales reaching $13.34 billion, highlighting consistent growth across immunology, oncology, and neuroscience franchises.

AbbVie faces several significant challenges that contribute to a negative outlook on its stock, including potential commercial execution failures for key assets such as Skyrizi, Rinvoq, and Botox, which could hinder revenue growth. The strong competition in the oncology space, particularly for Imbruvica, combined with limited market penetration of key products and macroeconomic pressures on the aesthetics segment, raises concerns about future earnings. Additionally, the company may experience pipeline delays and regulatory setbacks that could impair its ability to maintain long-term guidance, along with external economic influences that may further destabilize its financial performance.